Web annex 5: Oxytocin and ergometrine versus placebo or no treatment
Evidence to decision framework
Web annex 2: Carbetocin versus placebo or no treatment
Evidence to decision framework
Sepsis remains a leading cause of mortality and morbidity, especially during the first five days of life and in low and middle-income countries (LMIC) [1]. Hospital infection also remains a major cause of mortality in children despite progress encountered in the last decades.
Adolescent girls and young women (AGYW) remain disproportionately affected by HIV in Eastern and Southern Africa (ESA), with 26 per cent of new infections attributed to this population. AGYW face many personal, social and structural barriers to access, uptake and use of traditional HIV prevention me...thods. Oral Pre-exposure Prophylaxis (PrEP) is proven to be highly effective as an additional prevention choice for reducing the risk of HIV acquisition, including for AGYW. Successful uptake and adherence to PrEP is critical in its effectiveness as an HIV prevention method, however, the current demand for PrEP by AGYW is low with suboptimal adherence.
Within the ESA region, there is currently great impetus to address these challenges and scale up PrEP for AGYW. A critical aspect of this is to leverage the learnings and evidence from implementation of how to improve the demand and quality of PrEP programming for this population. Improving the Quality of Pre-Exposure Prophylaxis Implementation for Adolescent Girls and Young Women in Eastern and Southern Africa examines the current efforts in the region to accelerate and scale up evidence-based PrEP delivery platforms. The implementation brief provides current knowledge and builds on WHO guidance to provide key considerations for implementation, including driving demand and improving quality, as well as focus on wider combination prevention and integration agendas.
more
More than 700 000 people lose their life to suicide every year. The world is not on track to reach the 2030 suicide reduction targets. WHO advocates for countries to take action to prevent suicide, ideally through a comprehensive national suicide prevention strategy. Governments and communities can ...contribute to suicide prevention by implementing LIVE LIFE – WHO’s approach to starting suicide prevention so that countries can build on it further to develop a comprehensive national suicide prevention strategy. The guide is for all countries, with or without a national suicide prevention strategy; national or local focal points for suicide prevention, mental health, alcohol or NCDs; and community stakeholders with a vested interest or who may already be engaged in implementing suicide prevention activities.
Excecutive Summary available in English, French, Arabic, Chinese, Russian and Spanisch here:
more
Cada año, más de 700.000 personas pierden la vida por suicidio, la cuarta causa principal de mortalidad entre las personas de 15 a 29 años y la tercera entre las niñas de 15 a 19 años. La reducción de la tasa mundial de mortalidad por suicidio en un tercio para el 2030 es un indicador de los O...bjetivos de Desarrollo Sostenible de las Naciones Unidas, pero el mundo no está bien encaminado para lograr las metas mundiales y muchas más personas perderán la vida por una causa evitable. La OMS ha elaborado esta guía a fin de apoyar a los países para que ejecuten intervenciones eficaces clave basadas en la evidencia usando como punto de partida el enfoque multisectorial VIVIR LA VIDA, que les permitirá establecer una respuesta nacional integral para prevenir el suicidio.
Excecutive Summary available in English, French, Arabic, Chinese, Russian and Spanisch here:
more
Model Chapter for textbooks for medical students and allied health professionals
Recommandations pour une approche de santé publique
Guidance for the preparation and submission of dossiers
The first important change is a new priority ranking of the available medicines for MDR-TB treatment, based on a careful balance between expected benefits and harms. Treatment success for MDR-TB is currently low in many countries. This could be increased by improving access to the highest-ranked med...icines for all patients with MDR-TB.
more
Journal of The Association of Physicians of India, Vol. 63 November 2015,, pp.77-96
The global burden of disease due to mental disorders continues to rise, especially in low- and middle-income countries (LMIC). In addition to causing a large proportion of morbidity, mental disorders – especially severe mental disorders (SMD) – are linked with poorer health outcomes and increase...d mortality. SMD are defined as a group of conditions that include moderate to severe depression, bipolar disorder, and schizophrenia and other psychotic disorders. People with SMD have a two to three times higher average mortality compared to the general population, which translates to a 10-20 year reduction in life expectancy. While people with SMD do have higher rates of death due to unnatural causes (accidents, homicide, or suicide) than the general population, the
majority of deaths amongst people with SMD are attributable to physical health conditions, both
non-communicable and communicable.
more
This user guide is designed to provide national malaria control programmes with general information on glucose-6-phosphate dehydrogenase (G6PD) deficiency. Individuals with this condition may be at risk of adverse effects from medicines commonly used to cure Plasmodium vivax malaria, as well as from... other medicines and substances.
more
Dialogues Clin Neurosci. 2017 Jun; 19(2): 93–107.
Responses to epidemics, emergencies and disasters raise many ethical issues for the people involved, including public health specialists and policy makers. This training manual provides material on ethical issues in research, surveillance and patient care in these difficult contexts.
Q8.SCOPING QUESTION: In adults and older adolescents with depressive disorder, what is the comparative effectiveness of different formats of psychological treatments?